BioSight
Companies
Terns Pharmaceuticals, Inc. logo

TERN

NASDAQFOSTER CITY, CA
Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals develops pharmaceutical products across multiple therapeutic areas using various drug modalities. The company has product candidates in clinical development stages, with ongoing clinical trials and regulatory development plans underway. Terns is subject to a proposed acquisition by Merck Sharp & Dohme LLC.

Price history not yet available for TERN.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar